Document is current
Any future updates will be listed below
-
Authors
Hettwer, M. D. https://orcid.org/0000-0002-7973-6752
Larivière, S.
Park, B. Y. https://orcid.org/0000-0001-7096-337X
van den Heuvel, O. A. https://orcid.org/0000-0002-9804-7653
Schmaal, L. https://orcid.org/0000-0001-9822-048X
Andreassen, O. A. https://orcid.org/0000-0002-4461-3568
Ching, C. R. K.
Hoogman, M.
Buitelaar, J.
van Rooij, D.
Veltman, D. J.
Stein, D. J. https://orcid.org/0000-0001-7218-7810
Franke, B. https://orcid.org/0000-0003-4375-6572
van Erp, T. G. M. https://orcid.org/0000-0002-2465-2797
,
,
van Rooij, D.
,
,
,
van den Heuvel, O. A.
,
van Erp, T. G. M.
Jahanshad, N.
Thompson, P. M.
Thomopoulos, S. I.
Bethlehem, R. A. I. https://orcid.org/0000-0002-0714-0685
Bernhardt, B. C.
Eickhoff, S. B.
Valk, S. L. https://orcid.org/0000-0003-2998-6849
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung
Max-Planck-Gesellschaft
- License Information
-
More Information
Article History
Received: 16 February 2022
Accepted: 24 October 2022
First Online: 11 November 2022
Competing interests
: O.A.A. received speaker’s honorarium from Lundbeck and Sunovion, Consultant to HealthLytix. Jan Buitelaar has been a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen, and Servier. P.M.T. received grant support from Biogen, Inc., and consulting payments from Kairos Venture Capital, for work unrelated to the current paper. Other authors declare no competing interests.
